Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Operating Leases (2019 - 2026)

Ocular Therapeutix has reported Operating Leases over the past 8 years, most recently at $4.2 million for Q1 2026.

  • For Q1 2026, Operating Leases fell 13.07% year-over-year to $4.2 million; the TTM value through Mar 2026 reached $4.2 million, down 13.07%, while the annual FY2025 figure was $2.8 million, 47.33% down from the prior year.
  • Operating Leases for Q1 2026 was $4.2 million at Ocular Therapeutix, up from $2.8 million in the prior quarter.
  • Over five years, Operating Leases peaked at $8.7 million in Q4 2022 and troughed at $2.8 million in Q4 2025.
  • A 5-year average of $5.7 million and a median of $5.5 million in 2022 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: surged 57.29% in 2023 and later plummeted 47.33% in 2025.
  • Year by year, Operating Leases stood at $8.7 million in 2022, then fell by 20.74% to $6.9 million in 2023, then decreased by 22.29% to $5.3 million in 2024, then plummeted by 47.33% to $2.8 million in 2025, then surged by 50.27% to $4.2 million in 2026.
  • Business Quant data shows Operating Leases for OCUL at $4.2 million in Q1 2026, $2.8 million in Q4 2025, and $3.6 million in Q3 2025.